First National Daily eMedical Newspaper of India
Nobody Reports News Better Than Us  
Editorial (Dr SS Agarwal, Dr K K Aggarwal)
To Read the full story on emedinexus.com, or download our Android app or iOS app
2nd December 2016
Delhi High Court sets aside Centre's decision to ban 344 fixed dose combination medicines
Dec 1, 2016
 
The Delhi High Court has set aside the Centre's decision to ban 344 fixed dose combination (FDC) medicines, including well-known brands like Corex cough syrup, Vicks Action 500 Extra and D'Cold, reports TOI.  
 
The court gave the order after hearing arguments of companies like Pfizer, Glenmark, Procter and Gamble and Cipla, the central government and some NGOs like All India Drug Action Network (AIDAN).
 
The court had on March 14 stayed the Centre's March 10 ban on 344 FDC drugs and this interim order was passed in each and every case filed before it thereafter.
 
According to the drug companies, the government has not properly implemented the powers under section 26A (power to prohibit manufacture of drugs and cosmetics in public interest) of Drugs and Cosmetics Act, under which the ban was ordered. The ban order was passed without considering clinical data and the grounds that safer alternatives were available. The government had banned over 300 FDC drugs on the ground that they involve "risk" to humans and safer alternatives were available.
 
As per the March 10 notification, "On the basis of recommendations of an expert committee, the central government is satisfied that it is necessary and expedient in public interest to regulate by way of prohibition of manufacture for sale, sale and distribution for human use of said drugs in the country."
 
The Centre had argued that the FDC medicines are "new drugs" and thus, require licence from Drugs Controller General of India (DCGI) for sale and manufacture. Also there were no valid licences for making any of the banned FDCs and added it was difficult to implement any action at state level. However, it had also said that the lack of approval for these FDCs were a secondary issue and the primary focus was that they "lacked safety and efficacy" and thus, "ban was the only answer". According to them, the banned FDCs had no "therapeutic justification".
 
AIDAN, argued that there were nearly 40,000 FDC drugs in Indian market and since the regulatory control over such medicines was allegedly "illusory", the Centre's decision to ban some of them "was the only move". 
 
IMA View
IMA is only concerned with safety and quality of a drug. The job of DCGI is to maintain both. If the DCGI cannot take the guarantee of the quality and safety of any drug, how will doctors treat patients?
To Read More or Comment, Click Here
Top News
Practice Updates
Breaking sitting with light activities improves glycemic control in type 2 diabetes
Post upper airway surgery complications not associated with OSA severity
Testosterone treatment increases risk of venous thromboembolism
Discharge on the same day is safe post-laparoscopic acute non-perforated appendectomy
High blood glucose in early pregnancy associated with congenital heart disease in children
eMedi Humor
Medicolegal Corner
eMedi Quiz
 
a. Potassium level of 3.5 mEq/L 
b. Hematocrit of 35% 
c. Blood glucose level of 200 mg/dL 
d. White blood cell (WBC) count of 20,000/mm3
Webcasts 

Lifestyle Updates
 
Inspirational Story 1: The Seed of Honesty
Inspirational Story 2: An interesting story
Press Release
Management of osteoporosis

Osteoporosis, also called 'the silent disease' often goes unnoticed until the symptoms start to manifest. Early recognition of symptoms and preventive measures can help those who suffer.

New Delhi, Dec 01, 2016: Osteoporosis is a disease that causes bones to become abnormally thin, weakened, and prone to fractures. It is generally characterized by low bone density and degradation of bone tissue in terms of micro-architecture. Such a loss can make the bones fragile and increase the chances of fractures.

Osteoporosis shares a high burden in India, it is reported that there are currently over 230 million Indians over the age of 50 years, out of which 20% suffer from Osteoporosis. Estimates report that 1 out of 8 males and 1 out of 3 females in India suffers from osteoporosis, this essentially makes India one of the worst hit countries of the world.
To Read More or Comment, Click Here
IMA Updates